<DOC>
	<DOCNO>NCT02229227</DOCNO>
	<brief_summary>This Phase IIIb , randomize , open-label , parallel group , active control , multicenter , treat to-target study 26 week ' treatment duration evaluate efficacy safety once-weekly albiglutide replacement prandial insulin subject type 2 diabetes mellitus ( T2DM ) fail achieve adequate glycemic control current basal bolus insulin regimen ( without metformin ) . Approximately 794 subject randomly assign 1:1 ratio 1 2 treatment group : albiglutide + insulin glargine ( insulin lispro discontinuation Week 4 ) ( without metformin ) intensification insulin glargine + insulin lispro ( without metformin ) . The study comprise 4 study period : Screening ( 2 week ) , Standardization ( 4 week ) , Treatment ( 26 week ) , Post treatment Follow ( 4 week ) . The total duration subject 's participation approximately 36 week .</brief_summary>
	<brief_title>Safety Efficacy Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Male female , 18 year age old ( inclusive time Screening ) T2DM HbA1c &gt; = 7.0 % &lt; = 9.0 % Screening . Currently treat basalbolus insulin regimen ( without metformin ) least 3 month Screening . The subject must take follow : Basal insulin ( 1 2 daily injection neutral protamine Hagedorn insulin , insulin glargine , insulin detemir , insulin degludec ) AND Bolus insulin ( least 2 injection regular insulin , insulin glulisine , insulin aspart , insulin lispro ) total daily dose bolus insulin &lt; = 70 unit In addition , total daily dose insulin must &lt; = 140 unit If take metformin , stable dose least 8 week Screening Note : Subject receive antidiabetic medication within 30 day screen ( e.g. , glucagonlike peptide1 receptor ( GLP1R ) agonist , dipeptidyl peptidaseIV inhibitor , SU , thiazolidinedione ) . Subjects receive commercially available premixed basal prandial insulin eligible study . Fasting Cpeptide &gt; = 0.8 nanogram ( ng ) per milliliter ( mL ) [ &gt; = 0.26 nanomoles per litre ( nmol/L ) ] Body mass index &lt; = 40 kilogram per square meter ( kg/m^2 ) Thyroidstimulating hormone ( TSH ) level normal clinically euthyroid demonstrated thyroid test ( e.g. , free T4 ) Female subject childbearing potential ( i.e. , surgically sterile and/or postmenopausal ) must practice adequate contraception ( define protocol ) duration participation study include 4week post treatment Followup Period.. Willing able comply study procedure include performance frequent selfmonitored blood glucose ( SMBG ) profile accord protocol Able willing provide write informed consent Type 1 diabetes mellitus History cancer full remission least 3 year Screening . ( A history squamous cell basal cell carcinoma skin treat cervical intraepithelial neoplasia I II allow ) Personal family history medullary thyroid carcinoma multiple endocrine neoplasia type 2 Current symptomatic biliary disease history acute chronic pancreatitis Severe gastroparesis , i.e. , require regular therapy within 6 month Screening History significant GI surgery opinion investigator likely significantly affect upper GI pancreatic function [ e.g. , gastric bypass banding , antrectomy , RouxenY bypass , gastric vagotomy , small bowel resection , surgery think significantly affect upper GI function ] History severe hypoglycemia unawareness Diabetic complication ( e.g. , active proliferative retinopathy severe diabetic neuropathy ) clinically significant abnormality ( include psychiatric disorder ) , opinion investigator , may pose additional risk administer investigational product Clinically significant CV and/or cerebrovascular disease within 3 month Screening include , limited , follow : Stroke transient ischemic attack Acute coronary syndrome ( myocardial infarction [ MI ] unstable angina responsive nitroglycerin ) Cardiac surgery percutaneous coronary procedure Current history heart failure ( New York Heart Association class III IV ) Alanine aminotransferase ( ALT ) &gt; 2.5 × upper limit normal ( ULN ) bilirubin &gt; 1.5 × ULN ( isolated bilirubin &gt; 1.5 × ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) Unstable liver disease ( define presence ascites , encephalopathy , coagulopathy , hypoalbuminemia , esophageal gastric varix , persistent jaundice ) , cirrhosis , know biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . ( Chronic stable hepatitis B C acceptable subject otherwise meet entry criterion active antiviral treatment [ e.g. , presence hepatitis B surface antigen positive hepatitis C test result within 3 month Screening ] ) Hemoglobin &lt; 11 gram ( g ) per ( dL ) [ &lt; 110 g/L ] male subject &lt; 10 g/dL ( &lt; 100 g/L ) female subject Screening Estimated glomerular filtration rate ( eGFR ) &lt; = 30 millilitre per minute per 1.73 square meter ( mL/min/1.73 m^2 ) ( calculate use Modification Diet Renal Disease [ MDRD ] formula ) Screening Note : As use metformin subject vary degree renal function may differ country country , use metformin accordance metformin product label within participate country . Fasting triglyceride level &gt; 750 mg/dL Screening Hemoglobinopathy may affect proper interpretation HbA1c Known allergy albiglutide product component ( include yeast human albumin ) , GLP1 analogue , insulin , study medication 's excipients OR contraindication ( per prescribe information ) use potential study medication ( e.g. , insulin glargine , insulin lispro ) Use oral systemically injected glucocorticoid within 3 month randomization high likelihood requirement prolong treatment ( &gt; 1 week ) 6 month follow randomization . However , short course oral steroid ( single dose multiple dose 7 day ) may permit provided case discuss medical monitor . Inhaled , intraarticular , epidural , topical corticosteroid allow Female subject pregnant ( confirmed laboratory test ) lactate Receipt investigational drug within 30 day 5 halflives , whichever longer , Screening , history receipt investigational antidiabetic drug within 3 month randomization , receipt albiglutide previous study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>switch study</keyword>
	<keyword>albiglutide</keyword>
	<keyword>glucagon-like peptide-1 receptor agonist</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>basal-bolus insulin therapy</keyword>
</DOC>